Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Malayan Banking Bhd
OTC:MLYBY
|
MY |
|
Wuliangye Yibin Co Ltd
SZSE:000858
|
CN |
|
C
|
Com2uSCorp
KOSDAQ:078340
|
KR |
|
H
|
Hanil Cement Co Ltd
KRX:300720
|
KR |
|
G
|
Golden Bridge Electech Inc
TWSE:6133
|
TW |
|
Pharmacielo Ltd
XTSX:PCLO
|
CA |
|
H
|
Hammerson PLC
OTC:HMSNF
|
UK |
Clarity Pharmaceuticals Ltd
EPS (Diluted)
Clarity Pharmaceuticals Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
EPS (Diluted)
-AU$1
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Nyrada Inc
ASX:NYR
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
See Also
What is Clarity Pharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
-0.2
AUD
Based on the financial report for Jun 30, 2025, Clarity Pharmaceuticals Ltd's EPS (Diluted) amounts to -0.2 AUD.
What is Clarity Pharmaceuticals Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-46%
Over the last year, the EPS (Diluted) growth was -33%. The average annual EPS (Diluted) growth rates for Clarity Pharmaceuticals Ltd have been -26% over the past three years , -46% over the past five years .
